

ICAA CONFERENCE 2018

The 6th International Cerebral Amyloid Angiopathy & related disorders Conference
PROGRAM

Thursday, September 6th 2018

Session 1 9:00-12:45

9:00 Official opening of the conference

Dean Gosset

HCHWA-D

*Moderators: Mark van Buchem (Leiden, NL)
& Gaël Nicolas (Rouen, FR)*

9:15 Introductory talk

Sanne Van Rijn (HCHWA-D Patient Organization)

9:25 Imaging markers of presymptomatic HCHWA-D patients.

Sanneke van Rooden (Leiden, NL)

9:55 Anti-sense oligonucleotide treatment in HCHWA-D.

Willeke van Roon (Leiden, NL)

10:25 Hereditary cerebral amyloid angiopathy (HCAA)-type mutations increase β -amyloid's binding affinity for fibrinogen, delayed fibrinolysis, and fibrin deposit formation in the brains of HCAA patients.

Hyung Jin Ahn (New-York, USA)

10:35 CO₂-challenge measured with dual echo arterial spin labeling as a whole brain biomarker of cerebrovascular reactivity in HCHWA-D.

Sophie Schmid (Leiden, NL)

10:45 Novel CAA-specific compounds for PET imaging: an update on a preclinical study in APP/PS1 mice.

Milos Ikonovic (pittsburgh, PA, USA)

10:55 Coffee Break

Moderator: Hameed Sohradi (Perth, AU) & Marieke Wermer (Leiden, NL)

11:15 PiB-PET imaging in HCHWA-D in Australia and the Netherlands.

Jasmeer Chhatwal (Boston, MA, USA)

11:45 Candidate therapy studies for Icelandic-type hereditary CAA.

Hakon Hakonarson (Philadelphia, PA, USA)

12:15 Cerebral amyloid angiopathy influences clinical phenotype in familial Alzheimer's disease.

Natalie S Ryan (London, UK)

12:25 Imaging characteristics of duplication of the APP.

Lou Grangeon (Rouen, FR)

12:35 Feasibility of an active immunization clinical trial with a vaccine targeting amyloid- β vaccine in patients with HCHWA-D.

Kawita Kanhai

12:45 Lunch Break

Session 2 14:00- 17:20

Biomarkers of CAA

Moderators: Fabrizio Piazza (Milan, IT) & Susanna Schraen (Lille, FR)

14:00 MRI Correlates of Autopsy-proven CAA.

Konstantinos Arfanakis (Chicago, IL, USA)

14:30 New Insights from PET Molecular Imaging of CAA.

Anand Viswanathan (Boston, MA, USA)

15:00 Blood-brain barrier leakage and microvascular lesions in cerebral amyloid angiopathy - A post mortem MRI and histopathology study.

Whitney M. Freeze (Boston, USA)



INTERNATIONAL
caa
ASSOCIATION



Université
de Lille



15:10 Evidence for human transmission of amyloid- β cerebral amyloid angiopathy.

Zane Jaunmuktane (London, UK)

15:20 Comparing whole-brain susceptibility patterns in patients with Alzheimer's disease & cerebral amyloid angiopathy: a QSM study.

Valentina Perosa (Magdeburg, Germany)

15:30 Coffee Break

Moderators: Grégoire Boulouis (Paris, FR), & Marialuisa Zedde (IT)

16:00 Novel body fluid biomarkers for CAA: discovery and clinical implications.

Marcel Verbeek (Nijmegen, NL)

16:30 Biomarkers of Cognitive Dysfunction in CAA.

Yael Reijmer (Utrecht, NL)

17:00 Blood Metabolomic Profiling in Cerebral Amyloid Angiopathy, Alzheimer's Disease, and Controls.

Shuang Zhao (Alberta, Canada)

17:10 Cerebellar Hemorrhagic Distribution as a New Imaging Marker for Cerebral Amyloid Angiopathy.

Hsin-Hsi Tsa i (Taipei, Taiwan)

17:20 End of the day

20:00 Gala dinner

Friday, September 7th 2018

Session 3 9:00-12:30

CAA Biology and Physiology

Moderators: Susanne van Veluw (Boston, USA) & Vincent Berezowski (Lille, FR)

9:00 Effect of biological variants of ApoJ and ApoA-I in experimental models of cerebral β -amyloidosis

Mar Hernandez-Guillamon (Barcelona, ES)

9:30 Vasoactive properties of amyloid β isoforms correlate with their specific expression in CAA

Lieke Jäkel (Nijmegen, NL)

10:00 Silent cerebral microbleeds induce long-term cognitive decline in the non-diseased mouse.

Maud Pétrault (Lille, FR)

10:10 Connexin 43 and Cx43-20kDa isoform lead to vascular injury in cerebral amyloid angiopathy.

Anuska Andjelkovic. (Ann Arbor MI, USA)

10:20 Apolipoprotein D: a potential biomarker for cerebral amyloid angiopathy.

H. Bea Kuiperij (Nijmegen, NL)

10:30 Coffee Break

Moderators: Roxana O Carare (Southampton, UK) & Régis Bordet (Lille, FR)

11:00 Artificial vessels as a model for CAA.

Jérôme Robert (Vancouver, CA)

11:30 Characterization of a novel transgenic rat model for CAA.

William van Nostrand, (Kingston, RI, USA)

12:00 Perlecan Domain V as a Novel Treatment for Diabetic Co-morbid Experimental CAA.

Gregory Bix (Lexington, KY)

12:10 Reduced vessel reactivity in mice with vascular A β deposition is associated with impaired paravascular clearance.

Susanne J. van Veluw (Boston, USA)

12:20 Cerebrovascular smooth muscle cells as the drivers of periarterial lymphatic drainage of the brain.

Roxana Aldea, (University of Kentucky, USA)

12:30 Lunch break



INTERNATIONAL
caa
ASSOCIATION

CAA
DUTCH CAA FOUNDATION

Université
de Lille



CHU
LILLE

Lille FHU-VasCog
Lille - Hopital Pasteur Lille - Université Lille III

LiCEND
Lille Centre of Excellence
for Neurodegenerative Diseases

ADRINORD

Session 4 14:00-17.00

Clinical Implications and Therapeutic Dilemmas

Moderators: Karin Klijn (Nijmegen, NL) and Edip Guroi (Boston, USA)

14:00 Can we anticoagulate CAA patients in the context of atrial fibrillation?

Rustam Al-Shahi Salman (Edinburgh, UK)

14:30 Cognitive impairment in CAA patients: towards a diagnostic and therapeutic approach?

Jérémie Pariente (Toulouse, FR)

15:00 A Cohort Study on the Natural History of Cerebral Amyloid Angiopathy-related inflammation: Evaluation of the Long-Term Outcomes of Immunosuppressive Therapy.

Fabrizio Piazza (Milano, Italy)

15:10 Serum anti-A β antibody signatures in cerebral amyloid angiopathy manifestations.*

Yannick Chantran (Paris,FR)

15:20 Cognitive profile of MCI patients with cerebral amyloid angiopathy: An ancillary study of the BALTAZAR cohort.

Géraldine Buard (Lille, FR)

15:30 Coffee Break

Moderators: Grégrory Kuchcinsky (Lille, FR) & Ellis van Etten (Leiden, NL)

16:00 Transient focal neurological episodes: how to recognize and how to treat?

Speaker: Eric Smith (Calgary, CA)

16:30 The difficult diagnosis of CAA related inflammation

Part 1: Diagnosis

Speaker: Auriel Eytan (Tel Aviv, Israel)

Part 2: Treatment

Speaker: Sonia Alamowitch (Paris, FR)

17:00 Poster walk

17:30 End of the day

Saturday, September 8th 2018

Session 5 9:00-12:30

Emerging Diagnostic Methods for CAA

Moderators: Steve Greenberg (Boston, USA) & Stephanie Bombois (Lille, FR)

9:00 CT-based criteria for CAA.

Mark Rodrigues (Edinburgh, UK)

9:30 Guidelines for cortical superficial siderosis detection, rating and classification.

Frank Wollenweber (Munich, DE)

10:00 Subarachnoid extension of lobar hemorrhage on MRI in the acute and subacute phase is associated with the presence of criteria of probable cerebral amyloid angiopathy.

Dimitri Renard (Nimes, France)

10:10 Blood begets blood”: Cortical superficial siderosis progression in a prospective cohort of cerebral amyloid angiopathy.

Thanakit Pongpitakmetha (Boston, USA)

10:20 Cerebellar microbleeds distribution and cerebral amyloid angiopathy: an MRI and pathology-based study.

Marco Pasi (Boston, USA)

10:30 Coffee Break

Moderators: David Werring (London, UK) and Sarah Shams (Stockholm, SE)

11:00 Incidence of cerebral microbleeds and amyloid burden: the Mayo Clinic Study of Aging.

Jonathan Graff-Radford (Mayo Clinic, USA)

11:10 Texture-based Individual-level Classification of Normal-Appearing White Matter and White Matter Hyperintensities in Cerebral Amyloid Angiopathy and Healthy Controls.

Klourfeld E (Calgary, Canada)

11:20 Pathologic lesions associated with clinical impairment.

Julie Schneider (Chicago, IL, USA)

11:50 Boston Criteria version 2.1.

Andreas Charidimou (Boston, MA, USA)

12:30 Conclusion & ICAA 2020

12:45 End of the conference



This meeting is endorsed by the European Stroke Organization.

It is open to all who are interested in cerebrovascular diseases. <http://www.eso-stroke.org/>

Link to the next ESO Conference: <http://eso.kenes.com/>

This conference is supported by



Biogen

acetiam



 Bristol-Myers Squibb



**Boston
Scientific**



**Boehringer
Ingelheim**

NOVARTIS



INTERNATIONAL
caa
ASSOCIATION



**Université
de Lille**



**CHU
LILLE**



LICEND
LILLE CENTRE OF EXCELLENCE
FOR NEURODEGENERATIVE DISEASES

